.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ advanced breast cancer cells and also active or even secure mind metastases revealed regular intracranial task as well as systemic efficacy of T-DXd.